Codexis. has filed a patent for transaminase polypeptides capable of aminating a dicarbonyl substrate. The engineered transaminase polypeptide described in the claim has a specific amino acid sequence and residue differences compared to a reference sequence. The patent also covers polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides. GlobalData’s report on Codexis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Codexis, Bioethanol production GMOs was a key innovation area identified from patents. Codexis's grant share as of September 2023 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230313155A1) describes an engineered transaminase polypeptide with specific amino acid sequences and residue differences. The polypeptide has at least 80% sequence identity to a reference sequence (SEQ ID NO:4) and differs from it at residue position X136. Additionally, the amino acid residue at residue position X284 can be selected from A, G, P, S, T, or V.
Claim 2 specifies that the engineered transaminase polypeptide includes X136L, indicating a specific amino acid substitution at residue position X136. Claim 3 further expands on the amino acid sequence differences compared to SEQ ID NO:4, including various residue differences such as X42G, X54P, X69A, and others.
Claim 4 provides combinations of residue differences, such as X124W and X327L, X209M and X300G, X122F and X223V, and others. These combinations highlight specific amino acid substitutions in the engineered transaminase polypeptide.
Claim 5 mentions additional residue differences compared to SEQ ID NO:4, including X54A, X56D, X62N, X122F, X124K, X139E, and others. These differences contribute to the unique characteristics of the engineered transaminase polypeptide.
The patent also covers various compositions and vectors related to the engineered transaminase polypeptide. Claim 7 describes a composition comprising the engineered transaminase polypeptide, while claim 8 focuses on an engineered polynucleotide that encodes the polypeptide. Claim 9 introduces a vector that includes the engineered polynucleotide, and claim 10 specifies the inclusion of at least one control sequence in the vector.
Furthermore, the patent includes claims related to host cells. Claim 11 and claim 12 both describe host cells comprising the vector, with claim 11 specifying any host cell and claim 12 specifying an Escherichia coli cell. Finally, claim 13 and claim 14 specifically mention Escherichia coli cells as the host cells.
In summary, the patent describes an engineered transaminase polypeptide with specific amino acid sequences and residue differences. It covers various combinations and compositions involving the polypeptide, as well as vectors and host cells for its production. The patent's claims provide detailed information about the specific characteristics and variations of the engineered transaminase polypeptide.
To know more about GlobalData’s detailed insights on Codexis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
